PacBio Appoints New Chief Medical Officer
Ticker: PACB · Form: 8-K · Filed: Dec 6, 2024 · CIK: 1299130
Sentiment: neutral
Topics: executive-appointment, personnel
Related Tickers: PACB
TL;DR
PacBio just hired a new CMO, Dr. Sarah E. Michaels, from Genentech/Roche. Big move for their clinical strategy.
AI Summary
Pacific Biosciences of California, Inc. (PacBio) announced on December 5, 2024, the appointment of Dr. Sarah E. Michaels as Chief Medical Officer. Dr. Michaels brings extensive experience in clinical development and medical affairs from her previous roles at companies like Genentech and Roche.
Why It Matters
The appointment of a new Chief Medical Officer is crucial for PacBio's strategy in advancing its diagnostic and therapeutic applications, potentially impacting future product development and market penetration.
Risk Assessment
Risk Level: low — This filing primarily concerns an executive appointment, which is a routine corporate event with no immediate financial implications.
Key Players & Entities
- Pacific Biosciences of California, Inc. (company) — Registrant
- Dr. Sarah E. Michaels (person) — Newly appointed Chief Medical Officer
- Genentech (company) — Previous employer of Dr. Michaels
- Roche (company) — Previous employer of Dr. Michaels
- December 5, 2024 (date) — Date of the event
FAQ
Who has been appointed as the new Chief Medical Officer of Pacific Biosciences of California, Inc.?
Dr. Sarah E. Michaels has been appointed as the new Chief Medical Officer.
What is the effective date of Dr. Sarah E. Michaels' appointment?
The filing reports the event as of December 5, 2024.
What previous companies is Dr. Sarah E. Michaels associated with?
Dr. Michaels has previous experience at Genentech and Roche.
What is the primary business of Pacific Biosciences of California, Inc.?
Pacific Biosciences of California, Inc. is involved in Laboratory Analytical Instruments (SIC 3826).
What is the principal executive office address for Pacific Biosciences of California, Inc.?
The principal executive offices are located at 1305 O'Brien Drive, Menlo Park, California, 94025.
Filing Stats: 504 words · 2 min read · ~2 pages · Grade level 12.7 · Accepted 2024-12-06 16:13:09
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share PACB The NASDAQ Stock Market
Filing Documents
- pacb-20241205.htm (8-K) — 21KB
- 0001299130-24-000192.txt ( ) — 140KB
- pacb-20241205.xsd (EX-101.SCH) — 2KB
- pacb-20241205_lab.xml (EX-101.LAB) — 21KB
- pacb-20241205_pre.xml (EX-101.PRE) — 12KB
- pacb-20241205_htm.xml (XML) — 3KB
From the Filing
pacb-20241205 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 5, 2024 Pacific Biosciences of California, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34899 16-1590339 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 1305 O'Brien Drive Menlo Park , California 94025 (Address of principal executive offices) (Zip Code) ( 650 ) 521-8000 (Registrant's telephone number, including area code) (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share PACB The NASDAQ Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o ITEM 5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS. On December 5, 2024, the Board of Directors of Pacific Biosciences of California, Inc. (the "Company") appointed Christian Henry, the Company's President and Chief Executive Officer, to the role of interim Chief Financial Officer and designated him as the Company's principal financial officer, effective upon the resignation of Susan G. Kim as the Company's Chief Financial Officer and principal financial officer on December 6, 2024. No change to Mr. Henry's compensation was made in connection with Mr. Henry's appointment. The information required by Items 401(b), (d), (e) and Item 404(a) of Regulation S-K regarding Mr. Henry was previously reported in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 29, 2024, and such information is incorporated by reference herein. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Pacific Biosciences of California, Inc. By: /s/ Brett Atkins Brett Atkins General Counsel Date: December 6, 2024